Skip to main navigation Corporate Governance Governance Documents Sustainability Report Code of Conduct Corporate Governance Guidelines Nominating and Governance Committee Charter Audit Committee Charter Compensation Committee Charter Committees Composition Audit Committee Compensation Committee Nominating and Governance Committee Brian Birk Nominating and Governance Committee Wendy Johnson Audit Committee Tina Nova Audit Committee Compensation Committee Ebetuel (Beto) Pallares Nominating and Governance Committee Bruce Robertson Compensation Committee Nominating and Governance Committee Frank Stokes Audit Committee James Tullis Compensation Committee = Chairperson = Member Print Page Email Alerts RSS Feeds Investor Contacts © 2021 Exagen Inc. | All Rights Reserved SA1168 Footer

Skip to main navigation Investor Relations Corporate Profile We are dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. We have developed and are commercializing a portfolio of innovative testing products under our AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. CB-CAPs assess the activation of the complement system, a biological pathway that is widely implicated across many autoimmune and autoimmune related diseases, including systemic lupus erythematosus, or SLE. Our goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Our strategy includes leveraging our portfolio of testing products to market therapeutics through our sales channel and targeting the approximately 5,000 rheumatologists across the United States. Our business model of integrating testing products and therapeutics positions us to offer targeted solutions to rheumatologists and, ultimately, better serve patients. Nov 23, 2021 12:50 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Recent News Releases November 17, 2021 Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference November 10, 2021 Exagen Inc. Reports Third Quarter 2021 Results November 4, 2021 Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum VIEW MORE Upcoming Events More events are coming soon. VIEW MORE SEC Filings Governance FAQs Email Alerts Print Page Email Alerts RSS Feeds Investor Contacts © 2021 Exagen Inc. | All Rights Reserved SA1168 Footer